The effects of administration of dual long-acting bronchodilators (beta-agonists and muscarinic-antagonists), compared to mono therapy, on complex lung mechanics in patients with mild to moderate chronic obstructive pulmonary disease

Woolcock Institute of Medical Research0 个研究点目标入组 25 人开始时间: 2015年4月14日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Adults with physician-diagnosed mild-moderate chronic obstructive pulmonary disease, with a history of current or past smoking (total exposure > 10 pack years)

•* Use of glycopyrronium, indacaterol, salmeterol or any other LAMA or LABA within the previous 4 weeks (unless able to undergo a 2 week washout period)
•* Documented hypersensitivity to, or intolerance of, beta-agonists or anti-cholinergic therapies
•* Significant respiratory infection or documented exacerbation of COPD within the previous 6 weeks
•* Other active or chronic respiratory pathologies (for example, interstitial lung disease, asthma, chest wall pathology causing ventilatory restriction)
•* Past history of lung surgery (including lobectomy or pneumonectomy, but not lung biopsy) or thoracic radiation therapy (excluding isolated mediastinal radiation therapy with no evidence of subsequent pulmonary fibrosis)
•* Any major comorbidities deemed to impact on respiratory physiology or symptoms, including severe on uncontrolled heart failure, morbid obesity, muscular or neurological disorders causing respiratory muscle weakness or dysfunctional swallowing
•* History of severe renal or hepatic impairment
•* Unable to perform lung function testing at the enrollment visit
•* Dependence on domiciliary supplemental oxygen, unable to go without for at least 1 hour
•* Women who are breast feeding, pregnant, or unwilling to avoid pregnancy during the study period
•* Unable to provide informed consent
•* Current enrolment in other trials

发起方